Liver Stiffness by Transient Elastography Predicts Liver-Related Complications and Mortality in Patients with Chronic Liver Disease

Background Liver stiffness measurement (LSM) by transient elastography (TE, FibroScan) is a validated method for noninvasively staging liver fibrosis. Most hepatic complications occur in patients with advanced fibrosis. Our objective was to determine the ability of LSM by TE to predict hepatic complications and mortality in a large cohort of patients with chronic liver disease. Methods In consecutive adults who underwent LSM by TE between July 2008 and June 2011, we used Cox regression to determine the independent association between liver stiffness and death or hepatic complications (decompensation, hepatocellular carcinoma, and liver transplantation). The performance of LSM to predict complications was determined using the c-statistic. Results Among 2,052 patients (median age 51 years, 65% with hepatitis B or C), 87 patients (4.2%) died or developed a hepatic complication during a median follow-up period of 15.6 months (interquartile range, 11.0–23.5 months). Patients with complications had higher median liver stiffness than those without complications (13.5 vs. 6.0 kPa; P<0.00005). The 2-year incidence rates of death or hepatic complications were 2.6%, 9%, 19%, and 34% in patients with liver stiffness <10, 10–19.9, 20–39.9, and ≥40 kPa, respectively (P<0.00005). After adjustment for potential confounders, liver stiffness by TE was an independent predictor of complications (hazard ratio [HR] 1.05 per kPa; 95% confidence interval [CI] 1.03–1.06). The c-statistic of liver-stiffness for predicting complications was 0.80 (95% CI 0.75–0.85). A liver stiffness below 20 kPa effectively excluded complications (specificity 93%, negative predictive value 97%); however, the positive predictive value of higher results was sub-optimal (20%). Conclusions Liver stiffness by TE accurately predicts the risk of death or hepatic complications in patients with chronic liver disease. TE may facilitate the estimation of prognosis and guide management of these patients.

[1]  M McCarthy,et al.  Hepatology , 1999, Rapid Medicine.

[2]  A. Dreher Modeling Survival Data Extending The Cox Model , 2016 .

[3]  G. Kaplan,et al.  The feasibility and reliability of transient elastography using Fibroscan®: a practice audit of 2335 examinations. , 2014, Canadian journal of gastroenterology & hepatology.

[4]  V. de Lédinghen,et al.  Determination of reliability criteria for liver stiffness evaluation by transient elastography , 2013, Hepatology.

[5]  Laura E. Leggett,et al.  A health technology assessment of transient elastography in adult liver disease. , 2013, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.

[6]  A. Cucchetti,et al.  Value of Transient Elastography Measured With Fibroscan in Predicting the Outcome of Hepatic Resection for Hepatocellular Carcinoma , 2012, Annals of surgery.

[7]  J. Macías,et al.  Liver stiffness predicts clinical outcome in human immunodeficiency virus/hepatitis C virus‐coinfected patients with compensated liver cirrhosis , 2012, Hepatology.

[8]  Y. N. Park,et al.  Prediction of Liver-Related Events Using Fibroscan in Chronic Hepatitis B Patients Showing Advanced Liver Fibrosis , 2012, PloS one.

[9]  S. Mehta,et al.  Transient elastography for predicting clinical outcomes in patients with chronic liver disease , 2012, Journal of viral hepatitis.

[10]  A. Pollett,et al.  Feasibility and diagnostic performance of the FibroScan XL probe for liver stiffness measurement in overweight and obese patients , 2012, Hepatology.

[11]  J. Vinel,et al.  Liver stiffness accurately predicts portal hypertension related complications in patients with chronic liver disease: a prospective study. , 2011, Journal of hepatology.

[12]  J. Talwalkar,et al.  Biomarkers of liver fibrosis: What lies beneath the receiver operating characteristic curve? , 2011, Hepatology.

[13]  Julien Vergniol,et al.  Noninvasive tests for fibrosis and liver stiffness predict 5-year outcomes of patients with chronic hepatitis C. , 2011, Gastroenterology.

[14]  Y. N. Park,et al.  Risk assessment of hepatitis B virus–related hepatocellular carcinoma development using liver stiffness measurement (FibroScan) , 2011, Hepatology.

[15]  최은희,et al.  Risk assessment of hepatitis B virus-related hepatocellular carcinoma development using liver stiffness measurement (FibroScan). , 2011 .

[16]  P. Crotty,et al.  Transient elastography for the noninvasive assessment of liver fibrosis: a multicentre Canadian study. , 2010, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.

[17]  G. Alexander,et al.  Enhanced liver fibrosis test can predict clinical outcomes in patients with chronic liver disease , 2010, Gut.

[18]  T. Heeren,et al.  Noninvasive Markers of Liver Fibrosis Are Highly Predictive of Liver-Related Death in a Cohort of HCV-Infected Individuals With and Without HIV Infection , 2010, The American Journal of Gastroenterology.

[19]  V. de Lédinghen,et al.  Pitfalls of liver stiffness measurement: A 5‐year prospective study of 13,369 examinations , 2010, Hepatology.

[20]  H. Quan,et al.  Epidemiology and natural history of primary biliary cirrhosis in a Canadian health region: A population‐based study , 2009, Hepatology.

[21]  N. Kato,et al.  Prospective risk assessment for hepatocellular carcinoma development in patients with chronic hepatitis C by transient elastography , 2009, Hepatology.

[22]  R. Ehman,et al.  Abdominal Magnetic Resonance Elastography , 2009, Topics in magnetic resonance imaging : TMRI.

[23]  Hude Quan,et al.  Predicting in‐hospital mortality in patients with cirrhosis: Results differ across risk adjustment methods , 2009, Hepatology.

[24]  Y. Ngo,et al.  Diagnostic and prognostic values of noninvasive biomarkers of fibrosis in patients with alcoholic liver disease , 2009, Hepatology.

[25]  H. Quan,et al.  Impact of liver disease, alcohol abuse, and unintentional ingestions on the outcomes of acetaminophen overdose. , 2008, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[26]  H. Quan,et al.  Assessing validity of ICD-9-CM and ICD-10 administrative data in recording clinical conditions in a unique dually coded database. , 2008, Health services research.

[27]  Y. Ngo,et al.  An Accurate Definition of the Status of Inactive Hepatitis B Virus Carrier by a Combination of Biomarkers (FibroTest-ActiTest) and Viral Load , 2008, PloS one.

[28]  J M Peron,et al.  Transient elastography accurately predicts presence of significant portal hypertension in patients with chronic liver disease , 2008, Alimentary pharmacology & therapeutics.

[29]  A. fong,et al.  Utilization rates, complications and costs of percutaneous liver biopsy: a population‐based study including 4275 biopsies , 2008, Liver international : official journal of the International Association for the Study of the Liver.

[30]  A. Shaheen,et al.  The burden of hepatitis C virus infection is growing: a Canadian population-based study of hospitalizations from 1994 to 2004. , 2008, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.

[31]  Eva Herrmann,et al.  Performance of transient elastography for the staging of liver fibrosis: a meta-analysis. , 2008, Gastroenterology.

[32]  G. Jung,et al.  Model for end-stage liver disease , 2008, Der Chirurg.

[33]  A. Shaheen,et al.  Validation of ICD-9-CM/ICD-10 coding algorithms for the identification of patients with acetaminophen overdose and hepatotoxicity using administrative data , 2007, BMC Health Services Research.

[34]  Giacomo Belli,et al.  Liver stiffness measurement predicts severe portal hypertension in patients with HCV‐related cirrhosis , 2007, Hepatology.

[35]  W. Kim,et al.  The model for end‐stage liver disease (MELD) , 2007, Hepatology.

[36]  Y. Ngo,et al.  A prospective analysis of the prognostic value of biomarkers (FibroTest) in patients with chronic hepatitis C. , 2006, Clinical chemistry.

[37]  N. Ganne-Carrié,et al.  Liver stiffness measurement selects patients with cirrhosis at risk of bearing large oesophageal varices. , 2006, Journal of hepatology.

[38]  V. de Lédinghen,et al.  Diagnosis of cirrhosis by transient elastography (FibroScan): a prospective study , 2005, Gut.

[39]  F. Oberti,et al.  A novel panel of blood markers to assess the degree of liver fibrosis , 2005, Hepatology.

[40]  A. Clouston,et al.  Steatosis: Co‐factor in other liver diseases , 2005, Hepatology.

[41]  V. de Lédinghen,et al.  Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. , 2005, Gastroenterology.

[42]  D. Schuppan,et al.  Serum markers detect the presence of liver fibrosis: a cohort study. , 2004, Gastroenterology.

[43]  G. Kaplan,et al.  Population-based study of the epidemiology of and the risk factors for pyogenic liver abscess. , 2004, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[44]  D. Thabut,et al.  Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C , 2004, Comparative hepatology.

[45]  Calyampudi Radhakrishna Rao,et al.  Advances in Survival Analysis , 2003, Handbook of Statistics.

[46]  V. Paradis,et al.  Sampling variability of liver fibrosis in chronic hepatitis C , 2003, Hepatology.

[47]  M. Ziol,et al.  Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. , 2003, Ultrasound in medicine & biology.

[48]  Ralph B. D'Agostino,et al.  Evaluation of the Performance of Survival Analysis Models: Discrimination and Calibration Measures , 2003, Advances in Survival Analysis.

[49]  J. Bruzzi,et al.  Liver biopsy. , 2001, The New England journal of medicine.

[50]  C. Steiner,et al.  Comorbidity measures for use with administrative data. , 1998, Medical care.

[51]  Brämer Gr International statistical classification of diseases and related health problems. Tenth revision. , 1988, World health statistics quarterly. Rapport trimestriel de statistiques sanitaires mondiales.